Next Article in Journal
Unmasking the Mechanism behind Miltefosine: Revealing the Disruption of Intracellular Ca2+ Homeostasis as a Rational Therapeutic Target in Leishmaniasis and Chagas Disease
Previous Article in Journal
The Influence of Lysosomal Stress on Dental Pulp Stem Cell-Derived Schwann Cells
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomolecules
Volume 14
Issue 4
10.3390/biom14040407
biomolecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Correction to Biomolecules 2023, 13(8), 1179.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Liu et al. Emergent Peptides of the Antifibrotic Arsenal: Taking Aim at Myofibroblast Promoting Pathways. Biomolecules 2023, 13, 1179

by
Zhen Liu
1,†,
Xinyan Zhang
1,†,
Yanrong Wang
1,
Yifan Tai
1,
Xiaolin Yao
2 and
Adam C. Midgley
1,*
1
State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Bioactive Materials for the Ministry of Education, College of Life Sciences, Nankai University, Tianjin 300071, China
2
School of Food and Biological Engineering, Shaanxi University of Science and Technology, Xi’an 710021, China
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Biomolecules 2024, 14(4), 407; https://doi.org/10.3390/biom14040407
Submission received: 21 February 2024 / Accepted: 29 February 2024 / Published: 27 March 2024
Versions Notes
There was an error in the original publication [1]. One of the reviewed peptides, THR-184, completed phase 2 clinical trials in 2017, but for a different disease treatment. A correction has been made to Section 5. Discussion and Future Perspectives, paragraph 4:
“Most of the peptides reviewed here are in the preclinical stage of development and have yet to enter clinical trials. THR-184 and ANG-3777 (an HGF peptide mimetic previously known as BB3) have both completed phase 2 clinical trials (ClinicalTrials.gov ID: NCT01830920; NCT02771509) as perioperative treatments in cardiovascular-surgery-associated acute kidney injury (CVS-AKI), which is a type of ischemic injury that may progress to chronic kidney disease and renal fibrosis [59,60].”
With this change, two more references were added: [59] and [60] (see [2,3]), and the original [59] and [60] have been modified to [61] and [62].
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

References

  1. Liu, Z.; Zhang, X.; Wang, Y.; Tai, Y.; Yao, X.; Midgley, A.C. Emergent Peptides of the Antifibrotic Arsenal: Taking Aim at Myofibroblast Promoting Pathways. Biomolecules 2023, 13, 1179. [Google Scholar] [CrossRef] [PubMed]
  2. Carlson, W.D.; Keck, P.C.; Bosukonda, D.; Carlson, F.R. A Process for the Design and Development of Novel Bone Morphogenetic Protein-7 (BMP-7) Mimetics with an Example: THR-184. Front. Pharmacol. 2022, 13, 864509. [Google Scholar] [CrossRef] [PubMed]
  3. Ayad, S.; Neylan, J.F.; Mayne, T.J.; Gouveia, D.; Swaminathan, M. Hepatocyte Growth Factor Mimetic ANG-3777 for Cardiac Surgery–Associated Acute Kidney Injury. Kidney Int. Rep. 2022, 5, 2325–2332. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Liu, Z.; Zhang, X.; Wang, Y.; Tai, Y.; Yao, X.; Midgley, A.C. Correction: Liu et al. Emergent Peptides of the Antifibrotic Arsenal: Taking Aim at Myofibroblast Promoting Pathways. Biomolecules 2023, 13, 1179. Biomolecules 2024, 14, 407. https://doi.org/10.3390/biom14040407

AMA Style

Liu Z, Zhang X, Wang Y, Tai Y, Yao X, Midgley AC. Correction: Liu et al. Emergent Peptides of the Antifibrotic Arsenal: Taking Aim at Myofibroblast Promoting Pathways. Biomolecules 2023, 13, 1179. Biomolecules. 2024; 14(4):407. https://doi.org/10.3390/biom14040407

Chicago/Turabian Style

Liu, Zhen, Xinyan Zhang, Yanrong Wang, Yifan Tai, Xiaolin Yao, and Adam C. Midgley. 2024. "Correction: Liu et al. Emergent Peptides of the Antifibrotic Arsenal: Taking Aim at Myofibroblast Promoting Pathways. Biomolecules 2023, 13, 1179" Biomolecules 14, no. 4: 407. https://doi.org/10.3390/biom14040407

APA Style

Liu, Z., Zhang, X., Wang, Y., Tai, Y., Yao, X., & Midgley, A. C. (2024). Correction: Liu et al. Emergent Peptides of the Antifibrotic Arsenal: Taking Aim at Myofibroblast Promoting Pathways. Biomolecules 2023, 13, 1179. Biomolecules, 14(4), 407. https://doi.org/10.3390/biom14040407

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop